MUC16 and neoplasm: In this study, none of the patients (0%) experienced a CA125 response despite a clinical disease progression, which means that none of the patients would have continued treatment despite tumour progression if CA125 criteria rather than WHO criteria had been used for guidance of second-line therapy.